These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36399711)

  • 1. Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
    Burdett KB; Unruh D; Drumm M; Steffens A; Lamano J; Judkins J; Schwartz M; Javier R; Amidei C; Lipp ES; Peters KB; Lai A; Eldred BSC; Heimberger AB; McCortney K; Scholtens DM; Horbinski C
    Blood; 2023 Mar; 141(11):1322-1336. PubMed ID: 36399711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
    Watanabe J; Natsumeda M; Okada M; Kanemaru Y; Tsukamoto Y; Oishi M; Kakita A; Fujii Y
    World Neurosurg; 2019 Aug; 128():e982-e988. PubMed ID: 31100523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
    Mir Seyed Nazari P; Riedl J; Preusser M; Posch F; Thaler J; Marosi C; Birner P; Ricken G; Hainfellner JA; Pabinger I; Ay C
    J Thromb Haemost; 2018 Jun; 16(6):1121-1127. PubMed ID: 29676036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant IDH1 and thrombosis in gliomas.
    Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
    Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
    Diaz M; Jo J; Smolkin M; Ratcliffe SJ; Schiff D
    Neurology; 2021 Feb; 96(7):e1063-e1069. PubMed ID: 33361259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.
    Low SK; Anjum Z; Mahmoud A; Joshi U; Kouides P
    Thromb Res; 2022 Nov; 219():14-21. PubMed ID: 36088710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas.
    Ando K; Natsumeda M; Kawamura M; Shirakawa K; Okada M; Tsukamoto Y; Eda T; Watanabe J; Saito S; Takahashi H; Kakita A; Oishi M; Fujii Y
    Thromb Res; 2023 Mar; 223():36-43. PubMed ID: 36706720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
    Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.
    Riedl J; Ay C
    Semin Thromb Hemost; 2019 Jun; 45(4):334-341. PubMed ID: 31041803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.
    Thaler J; Ay C; Kaider A; Reitter EM; Haselböck J; Mannhalter C; Zielinski C; Marosi C; Pabinger I
    Neuro Oncol; 2014 Dec; 16(12):1645-51. PubMed ID: 24987133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.
    Huang Y; Ding H; Luo M; Li S; Xie C; Zhong Y; Li Z
    Support Care Cancer; 2022 Jul; 30(7):6063-6069. PubMed ID: 35419733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
    Drumm MR; Wang W; Sears TK; Bell-Burdett K; Javier R; Cotton KY; Webb B; Byrne K; Unruh D; Thirunavu V; Walshon J; Steffens A; McCortney K; Lukas RV; Phillips JJ; Mohamed E; Finan JD; Santana-Santos L; Heimberger AB; Franz CK; Kurz J; Templer JW; Swanson GT; Horbinski C
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37104042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
    Chen L; Voronovich Z; Clark K; Hands I; Mannas J; Walsh M; Nikiforova MN; Durbin EB; Weiss H; Horbinski C
    Neuro Oncol; 2014 Nov; 16(11):1478-83. PubMed ID: 24860178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
    Neal A; Kwan P; O'Brien TJ; Buckland ME; Gonzales M; Morokoff A
    Epilepsy Behav; 2018 Jan; 78():30-36. PubMed ID: 29172136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.